NewsBenzingaHC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220 HC Wainwright & Co. Maintains Buy on Inhibrx Biosciences, Lowers Price Target to $220 Benzinga 2026.11.16 12:33 (GMT+0) Open on Benzinga Other news HKMA, Swift Explore Cross-Border Tokenized Payments FirstSource Stock Outlook: Is Wall Street Bullish or Bearish? What Are Wall Street Analysts' Target Price for Alliant Energy Stock? Public Service Enterprise Stock: Analyst Estimates & Ratings Are Wall Street Analysts Bullish on FirstEnergy Stock? DuPont de Nemours Stock: Is Wall Street Bullish or Bearish?